DOCSLIB.ORG

48 14 5 5 4 9 Hsa-Mir-5001-5P -4.18 -4.18 N/A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
48 14 5 5 4 9 Hsa-Mir-5001-5P -4.18 -4.18 N/A Total Total 8mer 7mer-m8 7mer-A1 6mer Cumulative weighted Aggregate Target gene Representative transcript Gene name 3P-seq tags + 5 Representative miRNA context++ sites sites sites sites sites context++ score PCT score GIPC3 ENST00000322315.5 GIPC PDZ domain containing family, member 3 48 14 5 5 4 9 hsa-miR-5001-5p -4.18 -4.18 N/A GNG13 ENST00000248150.4 guanine nucleotide binding protein (G protein), gamma 13 5 7 0 7 0 0 hsa-miR-4498 -2.21 -2.21 N/A EVC ENST00000382674.2 Ellis van Creveld syndrome 165 15 0 15 0 1 hsa-miR-4498 -2.1 -2.1 N/A MAM domain containing glycosylphosphatidylinositol MDGA1 ENST00000297153.7 240 7 3 3 1 5 hsa-miR-5001-5p -2.05 -2.11 N/A anchor 1 KLK4 ENST00000324041.1 kallikrein-related peptidase 4 5 9 0 9 0 0 hsa-miR-4498 -1.77 -1.77 N/A OLFML2A ENST00000288815.5 olfactomedin-like 2A 155 9 4 4 1 1 hsa-miR-4498 -1.77 -1.77 N/A SDK2 ENST00000392650.3 sidekick cell adhesion molecule 2 8 5 3 2 0 2 hsa-miR-4498 -1.74 -1.74 N/A NKIRAS2 ENST00000462043.2 NFKB inhibitor interacting Ras-like 2 9685 4 1 3 0 1 hsa-miR-5001-5p -1.71 -1.71 N/A OSBP2 ENST00000382310.3 oxysterol binding protein 2 485 6 2 4 0 0 hsa-miR-5001-5p -1.64 -1.66 N/A SNPH ENST00000381873.3 syntaphilin 13 5 2 2 1 1 hsa-miR-4498 -1.61 -1.61 N/A SPN ENST00000360121.3 sialophorin 5 3 2 0 1 3 hsa-miR-5001-5p -1.58 -1.58 N/A PER2 ENST00000254658.3 period circadian clock 2 106 4 2 1 1 3 hsa-miR-4498 -1.57 -1.57 N/A FLJ27365 ENST00000360737.3 hsa-mir-4763 74 5 2 3 0 3 hsa-miR-4498 -1.5 -1.54 N/A UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, B3GALT5 ENST00000380620.4 5 9 2 5 2 3 hsa-miR-5001-5p -1.48 -1.48 N/A polypeptide 5 C19orf54 ENST00000470681.1 chromosome 19 open reading frame 54 18 4 1 3 0 3 hsa-miR-4498 -1.47 -1.5 N/A C17orf103 ENST00000468196.1 chromosome 17 open reading frame 103 54 7 4 1 2 1 hsa-miR-5001-5p -1.47 -1.47 N/A PRAF2 ENST00000376390.4 PRA1 domain family, member 2 1921 4 1 3 0 0 hsa-miR-4498 -1.45 -1.45 N/A C10orf91 ENST00000392630.3 chromosome 10 open reading frame 91 5 6 0 6 0 3 hsa-miR-4498 -1.43 -1.43 N/A HES6 ENST00000409574.1 hairy and enhancer of split 6 (Drosophila) 3170 5 1 3 1 3 hsa-miR-5001-5p -1.39 -1.4 N/A TNS4 ENST00000254051.6 tensin 4 40 4 2 2 0 4 hsa-miR-5001-5p -1.38 -1.94 N/A Uncharacterized protein; WD repeat domain AF196779.12 ENST00000376358.3 1921 4 1 3 0 0 hsa-miR-4498 -1.37 -1.37 N/A phosphoinositide-interacting protein 4 WDR45 ENST00000553851.1 WD repeat domain 45 1921 4 1 3 0 0 hsa-miR-4498 -1.37 -1.37 N/A MEN1 ENST00000377316.2 multiple endocrine neoplasia I 8 4 2 2 0 1 hsa-miR-4498 -1.34 -1.34 N/A GLTPD1 ENST00000343938.4 glycolipid transfer protein domain containing 1 4136 4 3 0 1 0 hsa-miR-5001-5p -1.33 -1.33 N/A NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4- NDUFA4L2 ENST00000556732.1 10 4 2 2 0 0 hsa-miR-5001-5p -1.3 -1.44 N/A like 2 Total Total 8mer 7mer-m8 7mer-A1 6mer Cumulative weighted Aggregate Target gene Representative transcript Gene name 3P-seq tags + 5 Representative miRNA context++ sites sites sites sites sites context++ score PCT score CPLX2 ENST00000359546.4 complexin 2 5 7 1 5 1 2 hsa-miR-4498 -1.29 -1.29 N/A AC174470.1 ENST00000457257.1 164 5 2 2 1 2 hsa-miR-5001-5p -1.27 -1.27 N/A PML ENST00000565898.1 promyelocytic leukemia 83 6* 0 3 2 3 hsa-miR-4498 -1.24 -1.24 N/A TTLL6 ENST00000433608.2 tubulin tyrosine ligase-like family, member 6 5 2 2 0 0 1 hsa-miR-5001-5p -1.24 -1.24 N/A CABP7 ENST00000216144.3 calcium binding protein 7 12 7 3 2 2 4 hsa-miR-5001-5p -1.23 -1.23 N/A RP11-706O15.1 ENST00000425492.2 HCG1981372, isoform CRA_c; Uncharacterized protein 142 2 1 1 0 0 hsa-miR-4498 -1.23 -1.23 N/A PAPLN ENST00000381166.3 papilin, proteoglycan-like sulfated glycoprotein 78 3 1 1 1 1 hsa-miR-5001-5p -1.22 -1.38 N/A ZNF618 ENST00000288466.7 zinc finger protein 618 778 6 0 4 2 2 hsa-miR-4498 -1.2 -1.22 N/A PRKACA ENST00000308677.4 protein kinase, cAMP-dependent, catalytic, alpha 12 3 1 2 0 2 hsa-miR-4498 -1.18 -1.18 N/A PACS1 ENST00000320580.4 phosphofurin acidic cluster sorting protein 1 87 7 1 5 1 5 hsa-miR-4498 -1.17 -1.42 N/A MARVELD1 ENST00000285605.6 MARVEL domain containing 1 2470 4 2 2 0 0 hsa-miR-5001-5p -1.17 -1.17 N/A RAB5A ENST00000273047.4 RAB5A, member RAS oncogene family 68 2 2 0 0 0 hsa-miR-5001-5p -1.17 -1.17 N/A TMEM234 ENST00000373593.1 transmembrane protein 234 51 4 1 3 0 0 hsa-miR-5001-5p -1.15 -1.15 N/A NPTXR ENST00000333039.2 neuronal pentraxin receptor 578 5 1 4 0 3 hsa-miR-4498 -1.13 -1.13 N/A PEX14 ENST00000356607.4 peroxisomal biogenesis factor 14 1637 7 0 7 0 0 hsa-miR-4498 -1.13 -1.13 N/A KIF1A ENST00000320389.7 kinesin family member 1A 115 3 1 1 1 1 hsa-miR-5001-5p -1.13 -1.21 N/A COL20A1 ENST00000422202.1 collagen, type XX, alpha 1 5 4 1 2 1 7 hsa-miR-4498 -1.12 -1.12 N/A BCL2L13 ENST00000418951.2 BCL2-like 13 (apoptosis facilitator) 741 4 0 4 0 3 hsa-miR-4498 -1.1 -1.11 N/A FOXK1 ENST00000328914.4 forkhead box K1 368 7* 2 3 1 5 hsa-miR-5001-5p -1.1 -1.22 N/A CHCHD5 ENST00000409719.1 coiled-coil-helix-coiled-coil-helix domain containing 5 1577 4 1 2 1 1 hsa-miR-4498 -1.1 -1.1 N/A ALX4 ENST00000329255.3 ALX homeobox 4 52 5 2 3 0 0 hsa-miR-4498 -1.09 -1.09 N/A ARNT2 ENST00000303329.4 aryl-hydrocarbon receptor nuclear translocator 2 39 6 1 2 3 2 hsa-miR-4498 -1.09 -1.09 N/A FAM222B ENST00000582266.1 family with sequence similarity 222, member B 100 5 0 2 3 4 hsa-miR-5001-5p -1.08 -1.09 N/A RPL14 ENST00000416518.1 ribosomal protein L14 8294 3 2 0 1 0 hsa-miR-5001-5p -1.08 -1.25 N/A TRIM66 ENST00000299550.6 tripartite motif containing 66 33 4 0 1 3 6 hsa-miR-5001-5p -1.08 -1.45 N/A Total Total 8mer 7mer-m8 7mer-A1 6mer Cumulative weighted Aggregate Target gene Representative transcript Gene name 3P-seq tags + 5 Representative miRNA context++ sites sites sites sites sites context++ score PCT score CCL19 ENST00000378800.3 chemokine (C-C motif) ligand 19 5 1 1 0 0 0 hsa-miR-5001-5p -1.07 -1.07 N/A TRIM62 ENST00000291416.5 tripartite motif containing 62 28 2 2 0 0 2 hsa-miR-5001-5p -1.07 -1.07 N/A PTPRF ENST00000372414.3 protein tyrosine phosphatase, receptor type, F 14842 4 0 2 2 1 hsa-miR-5001-5p -1.07 -1.07 N/A KRTAP10-9 ENST00000397911.3 keratin associated protein 10-9 5 2 1 1 0 1 hsa-miR-4498 -1.05 -1.05 N/A SYNDIG1L ENST00000331628.3 synapse differentiation inducing 1-like 7 5 1 3 1 0 hsa-miR-4498 -1.05 -1.05 N/A BBC3 ENST00000341983.4 BCL2 binding component 3 87 4 1 3 0 0 hsa-miR-4498 -1.04 -1.04 N/A KCNIP3 ENST00000295225.5 Kv channel interacting protein 3, calsenilin 555 6 2 3 1 1 hsa-miR-5001-5p -1.04 -1.04 N/A PTTG1IP ENST00000397887.3 pituitary tumor-transforming 1 interacting protein 1170 3 1 2 0 1 hsa-miR-5001-5p -1.04 -1.07 N/A PVRL1 ENST00000264025.3 poliovirus receptor-related 1 (herpesvirus entry mediator C) 50 7 2 4 1 0 hsa-miR-4498 -1.03 -1.13 N/A ALPK3 ENST00000258888.5 alpha-kinase 3 16 3 3 0 0 0 hsa-miR-5001-5p -1.03 -1.03 N/A RAB35 ENST00000534951.1 RAB35, member RAS oncogene family 1051 6 2 4 0 1 hsa-miR-4498 -1.02 -1.09 N/A RBBP8NL ENST00000252998.1 RBBP8 N-terminal like 5 2 1 0 1 2 hsa-miR-5001-5p -1.02 -1.02 N/A TJAP1 ENST00000372444.2 tight junction associated protein 1 (peripheral) 15 2 1 0 1 0 hsa-miR-5001-5p -1.02 -1.02 N/A TTBK1 ENST00000259750.4 tau tubulin kinase 1 7 5 1 4 0 0 hsa-miR-4498 -1.01 -1.01 N/A CX3CL1 ENST00000006053.6 chemokine (C-X3-C motif) ligand 1 218 5 0 5 0 1 hsa-miR-4498 -1.01 -1.04 N/A EEFSEC ENST00000483457.1 eukaryotic elongation factor, selenocysteine-tRNA-specific 625 4 3 1 0 3 hsa-miR-4498 -0.99 -1.22 N/A CLEC16A ENST00000409790.1 C-type lectin domain family 16, member A 108 4 2 1 1 4 hsa-miR-5001-5p -0.98 -1.17 N/A NF2 ENST00000347330.5 neurofibromin 2 (merlin) 828 6 0 4 2 0 hsa-miR-4498 -0.98 -1.16 N/A NFIC ENST00000346156.5 nuclear factor I/C (CCAAT-binding transcription factor) 26 9 0 8 1 6 hsa-miR-4498 -0.98 -1.27 N/A MUC5B ENST00000447027.1 mucin 5B, oligomeric mucus/gel-forming 5 1 1 0 0 0 hsa-miR-5001-5p -0.98 -0.98 N/A ZNF346 ENST00000503039.1 zinc finger protein 346 5 3 2 1 0 1 hsa-miR-5001-5p -0.98 -0.98 N/A SLC46A1 ENST00000440501.1 solute carrier family 46 (folate transporter), member 1 580 4 2 0 2 4 hsa-miR-5001-5p -0.98 -1 N/A FBXL16 ENST00000397621.1 F-box and leucine-rich repeat protein 16 5 4 0 3 1 1 hsa-miR-5001-5p -0.98 -0.98 N/A C2orf71 ENST00000331664.5 chromosome 2 open reading frame 71 5 2 1 0 1 1 hsa-miR-5001-5p -0.98 -0.98 N/A ARL2BP ENST00000219204.3 ADP-ribosylation factor-like 2 binding protein 450 2 2 0 0 0 hsa-miR-5001-5p -0.98 -1 N/A Total Total 8mer 7mer-m8 7mer-A1 6mer Cumulative weighted Aggregate Target gene Representative transcript Gene name 3P-seq tags + 5 Representative miRNA context++ sites sites sites sites sites context++ score PCT score ZMIZ2 ENST00000309315.4 zinc finger, MIZ-type containing 2 761 6 1 3 2 5 hsa-miR-4498 -0.97 -1.24 N/A CRTC1 ENST00000338797.6 CREB regulated transcription coactivator 1 322 6 2 4 0 1 hsa-miR-5001-5p -0.97 -0.99 N/A RAB37 ENST00000392610.1 RAB37, member RAS oncogene family 875 4 3 1 0 1 hsa-miR-5001-5p -0.97 -0.97 N/A TAGLN ENST00000532870.1 transgelin 225 2 1 0 1 1 hsa-miR-4498 -0.97 -0.99 N/A RUFY4 ENST00000441828.2 RUN and FYVE domain containing 4 5 4 1 3 0 1 hsa-miR-4498 -0.96 -0.96 N/A LMX1B ENST00000355497.5 LIM homeobox transcription factor 1, beta 8 5 1 3 1 1 hsa-miR-4498 -0.96 -0.96 N/A Transcription factor SOX-7; Uncharacterized protein; cDNA SOX7 ENST00000554914.1 47 4 0 2 2 2 hsa-miR-4498 -0.95 -0.98 N/A FLJ58508, highly similar to Transcription factor SOX-7 MS4A10 ENST00000308287.1 membrane-spanning 4-domains, subfamily A, member 10 5 2 2 0 0 1 hsa-miR-5001-5p -0.95 -0.95 N/A CNIH2 ENST00000528852.1
Load more

Recommended publications
  • Genome-Wide Association Study of Behavioral Disinhibition in a Selected Adolescent Sample Jaime Derringer *, Robin P. Corley
    Genome-wide association study of behavioral disinhibition in a selected adolescent sample Jaime Derringer1*, Robin P. Corley2, Brett C. Haberstick2, Susan E. Young2, Brittany Demmitt2, Daniel P. Howrigan3, Robert M. Kirkpatrick4, William G. Iacono5, Matt McGue5, Matthew Keller2, Sandra Brown6, Susan Tapert6, Christian J. Hopfer7, Michael C. Stallings2, Thomas J. Crowley7, Soo Hyun Rhee2, Ken Krauter2, John K. Hewitt2, Matthew B. McQueen2 1 University of Illinois Urbana-Champaign, 2 University of Colorado Boulder, 3 Massachusetts General Hospital/Harvard Medical School, 4 Virginia Commonwealth University, 5 University of Minnesota, 6 University of California San Diego, 7 University of Colorado Denver * Corresponding Author: Jaime Derringer, [email protected], Department of Psychology, University of Illinois Urbana-Champaign, Champaign IL USA 61820 Behavioral disinhibition GWAS 2 Abstract Behavioral disinhibition (BD) is a quantitative measure designed to capture the heritable variation encompassing risky and impulsive behaviors. As a result, BD represents an ideal target for discovering genetic loci that predispose individuals to a wide range of antisocial behaviors and substance misuse that together represent a large cost to society as a whole. Published genome-wide association studies (GWAS) have examined specific phenotypes that fall under the umbrella of BD (e.g. alcohol dependence, conduct disorder); however no GWAS has specifically examined the overall BD construct. We conducted a GWAS of BD using a sample of 1,901 adolescents over-selected for characteristics that define high BD, such as substance and antisocial behavior problems, finding no individual locus that surpassed genome-wide significance. Although no single SNP was significantly associated with BD, restricted maximum likelihood analysis estimated that 49.3% of the variance in BD within the Caucasian sub-sample was accounted for by the genotyped SNPs (p=0.06).
    [Show full text]
  • SUPPLEMENTAL DATA Supplemental Materials And
    SUPPLEMENTAL DATA Supplemental Materials and Methods Cells and Cell Culture Human breast carcinoma cell lines, MDA-MB-231 and MCF7, were purchased from American Type Tissue Culture Collection (ATCC). 231BoM-1833, 231BrM-2a, CN34, CN34-BoM2d, CN34-BrM2c and MCF7- BoM2d cell lines were kindly provided by Dr. Joan Massagué (Memorial Sloan-Kettering Cancer Center) (1-3). Luciferase-labeled cells were generated by infecting the lentivirus carrying the firefly luciferase gene. The immortalized mouse bone microvascular endothelial cell (mBMEC) was a generous gift from Dr. Isaiah J. Fidler (M.D. Anderson Cancer Center) (4). MCF10A and MCF10DCIS.com cells were purchased from ATCC and Asterand, respectively. MDA-MB-231, its variant cells, MCF7 and MCF-BoM2d cells were cultured in DMEM medium supplemented with 10% FBS and antibiotics. CN34 and its variant cells were cultured in Medium199 supplemented with 2.5% FBS, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 20 ng/ml EGF, 100 ng/ml cholera toxin and antibiotics. MCF10DCIS.com cells were cultured in RPMI-1640 medium supplemented with 10% FBS and antibiotics. MCF10A cells were cultured in MEGM mammary epithelial cell growth medium (Lonza). mBMEC was maintained at 8% CO2 at 33 °C in DMEM with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% non-essential amino acids and 1% vitamin mixture. Bone marrow stromal fibroblast cell lines HS5 and HS27A, and osteoblast cell line, hFOB1.19, were purchased from ATCC. Bone marrow derived human mesenchymal stem cells, BM-hMSC, were isolated for enrichment of plastic adherent cells from unprocessed bone marrow (Lonza) which was depleted of red blood cells.
    [Show full text]
  • Molecular Characterization of Acute Myeloid Leukemia by Next Generation Sequencing: Identification of Novel Biomarkers and Targets of Personalized Therapies
    Alma Mater Studiorum – Università di Bologna Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Dottorato di Ricerca in Oncologia, Ematologia e Patologia XXX Ciclo Settore Scientifico Disciplinare: MED/15 Settore Concorsuale:06/D3 Molecular characterization of acute myeloid leukemia by Next Generation Sequencing: identification of novel biomarkers and targets of personalized therapies Presentata da: Antonella Padella Coordinatore Prof. Pier-Luigi Lollini Supervisore: Prof. Giovanni Martinelli Esame finale anno 2018 Abstract Acute myeloid leukemia (AML) is a hematopoietic neoplasm that affects myeloid progenitor cells and it is one of the malignancies best studied by next generation sequencing (NGS), showing a highly heterogeneous genetic background. The aim of the study was to characterize the molecular landscape of 2 subgroups of AML patients carrying either chromosomal number alterations (i.e. aneuploidy) or rare fusion genes. We performed whole exome sequencing and we integrated the mutational data with transcriptomic and copy number analysis. We identified the cell cycle, the protein degradation, response to reactive oxygen species, energy metabolism and biosynthetic process as the pathways mostly targeted by alterations in aneuploid AML. Moreover, we identified a 3-gene expression signature including RAD50, PLK1 and CDC20 that characterize this subgroup. Taking advantage of RNA sequencing we aimed at the discovery of novel and rare gene fusions. We detected 9 rare chimeric transcripts, of which partner genes were transcription factors (ZEB2, BCL11B and MAFK) or tumor suppressors (SAV1 and PUF60) rarely translocated across cancer types. Moreover, we detected cryptic events hiding the loss of NF1 and WT1, two recurrently altered genes in AML. Finally, we explored the oncogenic potential of the ZEB2-BCL11B fusion, which revealed no transforming ability in vitro.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • Supplementary Methods
    Supplementary methods Human lung tissues and tissue microarray (TMA) All human tissues were obtained from the Lung Cancer Specialized Program of Research Excellence (SPORE) Tissue Bank at the M.D. Anderson Cancer Center (Houston, TX). A collection of 26 lung adenocarcinomas and 24 non-tumoral paired tissues were snap-frozen and preserved in liquid nitrogen for total RNA extraction. For each tissue sample, the percentage of malignant tissue was calculated and the cellular composition of specimens was determined by histological examination (I.I.W.) following Hematoxylin-Eosin (H&E) staining. All malignant samples retained contained more than 50% tumor cells. Specimens resected from NSCLC stages I-IV patients who had no prior chemotherapy or radiotherapy were used for TMA analysis by immunohistochemistry. Patients who had smoked at least 100 cigarettes in their lifetime were defined as smokers. Samples were fixed in formalin, embedded in paraffin, stained with H&E, and reviewed by an experienced pathologist (I.I.W.). The 413 tissue specimens collected from 283 patients included 62 normal bronchial epithelia, 61 bronchial hyperplasias (Hyp), 15 squamous metaplasias (SqM), 9 squamous dysplasias (Dys), 26 carcinomas in situ (CIS), as well as 98 squamous cell carcinomas (SCC) and 141 adenocarcinomas. Normal bronchial epithelia, hyperplasia, squamous metaplasia, dysplasia, CIS, and SCC were considered to represent different steps in the development of SCCs. All tumors and lesions were classified according to the World Health Organization (WHO) 2004 criteria. The TMAs were prepared with a manual tissue arrayer (Advanced Tissue Arrayer ATA100, Chemicon International, Temecula, CA) using 1-mm-diameter cores in triplicate for tumors and 1.5 to 2-mm cores for normal epithelial and premalignant lesions.
    [Show full text]
  • Misexpression of Cancer/Testis (Ct) Genes in Tumor Cells and the Potential Role of Dream Complex and the Retinoblastoma Protein Rb in Soma-To-Germline Transformation
    Michigan Technological University Digital Commons @ Michigan Tech Dissertations, Master's Theses and Master's Reports 2019 MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO-GERMLINE TRANSFORMATION SABHA M. ALHEWAT Michigan Technological University, [email protected] Copyright 2019 SABHA M. ALHEWAT Recommended Citation ALHEWAT, SABHA M., "MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO- GERMLINE TRANSFORMATION", Open Access Master's Thesis, Michigan Technological University, 2019. https://doi.org/10.37099/mtu.dc.etdr/933 Follow this and additional works at: https://digitalcommons.mtu.edu/etdr Part of the Cancer Biology Commons, and the Cell Biology Commons MISEXPRESSION OF CANCER/TESTIS (CT) GENES IN TUMOR CELLS AND THE POTENTIAL ROLE OF DREAM COMPLEX AND THE RETINOBLASTOMA PROTEIN RB IN SOMA-TO-GERMLINE TRANSFORMATION By Sabha Salem Alhewati A THESIS Submitted in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE In Biological Sciences MICHIGAN TECHNOLOGICAL UNIVERSITY 2019 © 2019 Sabha Alhewati This thesis has been approved in partial fulfillment of the requirements for the Degree of MASTER OF SCIENCE in Biological Sciences. Department of Biological Sciences Thesis Advisor: Paul Goetsch. Committee Member: Ebenezer Tumban. Committee Member: Zhiying Shan. Department Chair: Chandrashekhar Joshi. Table of Contents List of figures .......................................................................................................................v
    [Show full text]
  • Discovery of a Molecular Glue That Enhances Uprmt to Restore
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Discovery of a molecular glue that enhances UPRmt to restore proteostasis via TRKA-GRB2-EVI1-CRLS1 axis Authors: Li-Feng-Rong Qi1, 2 †, Cheng Qian1, †, Shuai Liu1, 2†, Chao Peng3, 4, Mu Zhang1, Peng Yang1, Ping Wu3, 4, Ping Li1 and Xiaojun Xu1, 2 * † These authors share joint first authorship Running title: Ginsenoside Rg3 reverses Parkinson’s disease model by enhancing mitochondrial UPR Affiliations: 1 State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 2 Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 3. National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China 4. Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai, 201204, China. Corresponding author: Ping Li, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Email: [email protected], Xiaojun Xu, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Telephone number: +86-2583271203, E-mail: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Sox2 Promotes Malignancy in Glioblastoma by Regulating
    Volume 16 Number 3 March 2014 pp. 193–206.e25 193 www.neoplasia.com Artem D. Berezovsky*, Laila M. Poisson†, Sox2 Promotes Malignancy in ‡ ‡ David Cherba , Craig P. Webb , Glioblastoma by Regulating Andrea D. Transou*, Nancy W. Lemke*, Xin Hong*, Laura A. Hasselbach*, Susan M. Irtenkauf*, Plasticity and Astrocytic Tom Mikkelsen*,§ and Ana C. deCarvalho* Differentiation1,2 *Department of Neurosurgery, Henry Ford Hospital, Detroit, MI; †Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI; ‡Program of Translational Medicine, Van Andel Research Institute, Grand Rapids, MI; §Department of Neurology, Henry Ford Hospital, Detroit, MI Abstract The high-mobility group–box transcription factor sex-determining region Y–box 2 (Sox2) is essential for the maintenance of stem cells from early development to adult tissues. Sox2 can reprogram differentiated cells into pluripotent cells in concert with other factors and is overexpressed in various cancers. In glioblastoma (GBM), Sox2 is a marker of cancer stemlike cells (CSCs) in neurosphere cultures and is associated with the proneural molecular subtype. Here, we report that Sox2 expression pattern in GBM tumors and patient-derived mouse xenografts is not restricted to a small percentage of cells and is coexpressed with various lineage markers, suggesting that its expression extends beyond CSCs to encompass more differentiated neoplastic cells across molecular subtypes. Employing a CSC derived from a patient with GBM and isogenic differentiated cell model, we show that Sox2 knockdown in the differentiated state abolished dedifferentiation and acquisition of CSC phenotype. Furthermore, Sox2 deficiency specifically impaired the astrocytic component of a biphasic gliosarcoma xenograft model while allowing the formation of tumors with sarcomatous phenotype.
    [Show full text]
  • Targeting the DEK Oncogene in Head and Neck Squamous Cell Carcinoma: Functional and Transcriptional Consequences
    Targeting the DEK oncogene in head and neck squamous cell carcinoma: functional and transcriptional consequences A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements to the degree of Doctor of Philosophy (Ph.D.) in the Department of Cancer and Cell Biology of the College of Medicine March 2015 by Allie Kate Adams B.S. The Ohio State University, 2009 Dissertation Committee: Susanne I. Wells, Ph.D. (Chair) Keith A. Casper, M.D. Peter J. Stambrook, Ph.D. Ronald R. Waclaw, Ph.D. Susan E. Waltz, Ph.D. Kathryn A. Wikenheiser-Brokamp, M.D., Ph.D. Abstract Head and neck squamous cell carcinoma (HNSCC) is one of the most common malignancies worldwide with over 50,000 new cases in the United States each year. For many years tobacco and alcohol use were the main etiological factors; however, it is now widely accepted that human papillomavirus (HPV) infection accounts for at least one-quarter of all HNSCCs. HPV+ and HPV- HNSCCs are studied as separate diseases as their prognosis, treatment, and molecular signatures are distinct. Five-year survival rates of HNSCC hover around 40-50%, and novel therapeutic targets and biomarkers are necessary to improve patient outcomes. Here, we investigate the DEK oncogene and its function in regulating HNSCC development and signaling. DEK is overexpressed in many cancer types, with roles in molecular processes such as transcription, DNA repair, and replication, as well as phenotypes such as apoptosis, senescence, and proliferation. DEK had never been previously studied in this tumor type; therefore, our studies began with clinical specimens to examine DEK expression patterns in primary HNSCC tissue.
    [Show full text]
  • Supplementary Table 1
    Protein Associated Description NC miR1 NC miR-1 Base 2 Log Name Gene Name Peptides Peptides PepHits PepHits of NC/miR-1 ENSP00000338413 UBA1 ubiquitin-like modifier activating enzyme 1 14 0 59 0 5.9 ENSP00000304592 FASN fatty acid synthase 33 1 99 1 5.6 ENSP00000296122 PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme 6 0 36 0 5.2 ENSP00000220849 EIF3E eukaryotic translation initiation factor 3, subunit E 9 0 35 0 5.2 ENSP00000346037 RPLP1 ribosomal protein, large, P1 1 0 32 0 5.0 ENSP00000262982 CSE1L CSE1 chromosome segregation 1-like 12 0 32 0 5.0 ENSP00000353157 septin 2 septin 2 5 0 28 0 4.9 ENSP00000326031 PPP1CA protein phosphatase 1, catalytic subunit, alpha isozyme 8 0 28 0 4.9 ENSP00000401802 PSMC6 proteasome (prosome, macropain) 26S subunit, ATPase, 6 8 0 28 0 4.9 ENSP00000327539 HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 5 0 28 0 4.9 ENSP00000335084 PPP1CC protein phosphatase 1, catalytic subunit, gamma isozyme 6 0 27 0 4.8 ENSP00000300648 GCN1L1 GCN1 general control of amino-acid synthesis 1-like 1 13 0 27 0 4.8 (yeast) ENSP00000358765 4 0 27 0 4.8 ENSP00000325002 COPG1 coatomer protein complex, subunit gamma 1 9 0 26 0 4.8 ENSP00000298852 PSMC3 proteasome (prosome, macropain) 26S subunit, ATPase, 3 5 0 24 0 4.6 ENSP00000322419 RPLP2 ribosomal protein, large, P2 4 1 47 1 4.6 ENSP00000307288 MCM7 minichromosome maintenance complex component 7 9 0 23 0 4.6 ENSP00000309474 PSMD1 proteasome (prosome, macropain) 26S subunit, non-ATPase, 8 0 22 0 4.5 1 ENSP00000358921 ACTR1A ARP1 actin-related protein 1 homolog
    [Show full text]
  • Immortalization of Common Marmoset Monkey Fibroblasts by Piggybac Transposition of Htert
    RESEARCH ARTICLE Immortalization of common marmoset monkey fibroblasts by piggyBac transposition of hTERT 1,2☯ 1☯¤a 3 3 Stoyan PetkovID , Tobias Kahland , Orr Shomroni , Thomas Lingner , Gabriela Salinas3, Sigrid Fuchs4, Katharina Debowski1¤b, RuÈ diger Behr1,2* 1 Platform Degenerative Diseases, German Primate Center- Leibniz Institute for Primate Research, GoÈttingen, Germany, 2 DZHK (German Center for Cardiovascular Research), Partner Site GoÈttingen, GoÈttingen, Germany, 3 Microarray and Deep-Sequencing Core Facility, University Medical Center GoÈttingen a1111111111 (UMG), GoÈttingen, Germany, 4 Department of Human Genetics, University Medical Center Hamburg- a1111111111 Eppendorf, Hamburg, Germany a1111111111 ☯ These authors contributed equally to this work. a1111111111 ¤a Current address: a-tune Software AG, Darmstadt, Germany a1111111111 ¤b Current address: STEMCELL Technologies Germany GmbH, Cologne, Germany * [email protected] Abstract OPEN ACCESS Citation: Petkov S, Kahland T, Shomroni O, Following a certain type-specific number of mitotic divisions, terminally differentiated cells Lingner T, Salinas G, Fuchs S, et al. (2018) undergo proliferative senescence, thwarting efforts to expand different cell populations in Immortalization of common marmoset monkey vitro for the needs of scientific research or medical therapies. The primary cause of this phe- fibroblasts by piggyBac transposition of hTERT. PLoS ONE 13(9): e0204580. https://doi.org/ nomenon is the progressive shortening of the telomeres and the subsequent activation of 10.1371/journal.pone.0204580 cell cycle control pathways leading to a block of cell proliferation. Restoration of telomere Editor: Gabriele Saretzki, University of Newcastle, length by transgenic expression of telomerase reverse transcriptase (TERT) usually results UNITED KINGDOM in bypassing of the replicative senescence and ultimately in cell immortalization.
    [Show full text]
  • Brian BW.Indd
    UNRAVELING MLL-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA BBrianrian BBW.inddW.indd 1 331-03-111-03-11 116:596:59 Unraveling MLL-rearranged Pediatric Acute Myeloid Leukemia © 2011 Brian V. Balgobind, Capelle aan den IJssel, Th e Netherlands ISBN 978-94-6169-051-7 Cover Design: Brian Balgobind Photo’s cover and chapters: www.f1-site.com Layout: Optima Grafi sche Communicatie, Rotterdam Printing: Optima Grafi sche Communicatie, Rotterdam Financial support for the print and reproduction of this thesis from the Pediatric Oncol- ogy Foundation Rotterdam (KOCR), Genzyme, Novartis Oncology and MRC Holland, is gratefully acknowledged. To perform the studies described in this thesis, B.V. Balgobind was fi nancially supported by the ‘Netherlands Organization for Scientifi c Research’ (NWO) and Pediatric Oncol- ogy Foundation Rotterdam (KOCR). No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission from the author or, when appropriate, from the publishers of the publications. BBrianrian BBW.inddW.indd 2 331-03-111-03-11 116:596:59 UNRAVELING MLL-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA Het ontrafelen van acute myeloïde leukemie met een MLL-gen herschikking in kinderen Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit te Rotterdam op gezag van de rector magnifi cus Prof.dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden woensdag 25 mei 2011 om 09.30 uur door Brian Vinod Balgobind geboren te Delfzijl BBrianrian BBW.inddW.indd 3 331-03-111-03-11 116:596:59 PROMOTIECOMMISSIE Promotor: Prof.dr.
    [Show full text]